PASD1 and acute myeloid leukemia: Our previous serological analysis of recombinant tumor cDNA expression libraries (SEREX) analysis of AML patient sera, identified SSX2IP and PASD1, as well as SSX2IP’s interacting partner, SSX2, as potential targets for the immunotherapy of myeloid leukemia [27].